At the 61st ASH Annual Meeting & Exposition, Naval Daver, MD Anderson Cancer Center, discusses his presentation: Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy.
1. What are the current therapeutic options for elderly patients with relapsed or refractory AML ineligible for chemotherapy? (0:05)
2. Could you tell us a little about the mechanism of action of idasanutlin? (1:24)
3. What is the rationale for the combination of venetoclax and idasanutlin? (2:50)
4. Could you tell us a little about the phase 1b study and its efficacy and safety findings? (4:36)
5. What progress has been made in identifying biomarkers of response to this combined therapy? (6:30)
Naval Daver has received consulting fees from Abbvie, Genentech, BMS, PFizer, Forty-Seven, DAiichi Sankyo, Astellas, Celgene and Novartis. He has received research funding from Abbvie, Genentech, BMS, PFizer, Forty-Seven, DAiichi Sankyo, Astellas, Celgene and Novartis.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Leukaemia
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘ Disclosures: Jorge Cortes is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!